0000950170-23-053875 Sample Contracts

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

Ovid Therapeutics Inc. • October 18th, 2023 • Pharmaceutical preparations

• Company
  Ovid Therapeutics Inc.
• Filed
  October 18th, 2023
• Industry
  Pharmaceutical preparations

Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously retaining 87% of the interest in soticlestat